UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Defining Left Bundle Branch Block in the Era of Cardiac Resynchronization Therapy

The American journal of cardiology, 2011-03, Vol.107 (6), p.927-934

2011

Volltextzugriff (PDF)

Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia Risk

PloS one, 2016-12, Vol.11 (12), p.e0166925

2016

Volltextzugriff (PDF)

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)

Clinical pharmacology and therapeutics, 2021-02, Vol.109 (2), p.319-333

2021

Volltextzugriff (PDF)

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

Journal of pharmacological and toxicological methods, 2016-09, Vol.81 (C), p.251-262

2016

Volltextzugriff (PDF)

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress

Journal of pharmacological and toxicological methods, 2016-09, Vol.81, p.15-20

2016

Volltextzugriff (PDF)

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

Cell reports (Cambridge), 2018-09, Vol.24 (13), p.3582-3592

2018

Volltextzugriff (PDF)

Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment

Toxicological sciences, 2022-11, Vol.190 (2), p.117-126

2022

Volltextzugriff (PDF)

Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study

Clinical pharmacology and therapeutics, 2018-01, Vol.103 (1), p.54-66

2018

Volltextzugriff (PDF)

Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

Toxicological sciences, 2017-01, Vol.155 (1), p.234-247

2017

Volltextzugriff (PDF)

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Clinical pharmacology and therapeutics, 2019-02, Vol.105 (2), p.466-475

2019

Volltextzugriff (PDF)

Evaluating kratom alkaloids using PHASE

PloS one, 2020-03, Vol.15 (3), p.e0229646

2020

Volltextzugriff (PDF)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

Frontiers in physiology, 2017-08, Vol.8, p.616-616

2017

Volltextzugriff (PDF)

A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm

Journal of biomolecular screening, 2016-01, Vol.21 (1), p.1-11

2016

Volltextzugriff (PDF)

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting

Clinical pharmacology and therapeutics, 2021-05, Vol.109 (5), p.1232-1243

2021

Volltextzugriff (PDF)

Mechanisms of sex and age differences in ventricular repolarization in humans

The American heart journal, 2014-11, Vol.168 (5), p.749-756.e3

2014

Volltextzugriff (PDF)

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block

PloS one, 2020-11, Vol.15 (11), p.e0241362-e0241362

2020

Volltextzugriff (PDF)

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation

Clinical and translational science, 2021-05, Vol.14 (3), p.1049-1061

2021

Volltextzugriff (PDF)

Associations of electrocardiographic P-wave characteristics with left atrial function, and diffuse left ventricular fibrosis defined by cardiac magnetic resonance: The PRIMERI Study

Heart rhythm, 2015, Vol.12 (1), p.155-162

2015

Volltextzugriff (PDF)

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment

Frontiers in physiology, 2017-11, Vol.8, p.917-917

2017

Volltextzugriff (PDF)

Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block

PloS one, 2016-12, Vol.11 (12), p.e0163619-e0163619

2016

Volltextzugriff (PDF)

Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers of IFNβ‐1a Biologics

Clinical pharmacology and therapeutics, 2023-01, Vol.113 (1), p.98-107

2023

Volltextzugriff (PDF)

Clinical Trial in a Dish: Personalized Stem Cell–Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT‐Prolonging Drugs

Clinical and translational science, 2019-11, Vol.12 (6), p.687-697

2019

Volltextzugriff (PDF)

Predicting potential adverse events using safety data from marketed drugs

BMC bioinformatics, 2020-04, Vol.21 (1), p.163-21, Article 163

2020

Volltextzugriff (PDF)

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

Therapeutic innovation & regulatory science, 2019-07, Vol.53 (4), p.519-525

2019

Volltextzugriff (PDF)

Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration

CPT: pharmacometrics and systems pharmacology, 2021-12, Vol.10 (12), p.1479-1484

2021

Volltextzugriff (PDF)

1 – 25 von 691

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(638)
Mit Volltextzugriff
(582)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(691)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Defining Left Bundle Branch Block in the Era of Cardiac Resynchronization Therapy

Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia Risk

Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment

Mechanistic Model‐Informed Proarrhythmic Risk Assessment of Drugs: Review of the “CiPA” Initiative and Design of a Prospective Clinical Validation Study

Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Evaluating kratom alkaloids using PHASE

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment

A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm

Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting

Mechanisms of sex and age differences in ventricular repolarization in humans

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block

Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation

Associations of electrocardiographic P-wave characteristics with left atrial function, and diffuse left ventricular fibrosis defined by cardiac magnetic resonance: The PRIMERI Study

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment

Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block

Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers of IFNβ‐1a Biologics

Clinical Trial in a Dish: Personalized Stem Cell–Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT‐Prolonging Drugs

Predicting potential adverse events using safety data from marketed drugs

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting

Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration

Suchergebnisse filtern